Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2026.1792686 Correction Correction: Comparison of HBV-specific T cell reactivity across the pregnant, postpartum and non-pregnant women with chronic HBV infection WangGenju 1 * † Resources Writing – review & editing Conceptualization Supervision Project administration YueFangping 2 † Methodology Investigation Writing – review & editing Data curation Formal analysis ZhangZiyue 1 Investigation Resources Writing – review & editing Data curation WuYandan 2 Writing – review & editing Methodology Formal analysis JiRuixue 2 Data curation Investigation Writing – review & editing ZhouGuanlun 1 Writing – review & editing Resources Data curation JiYing 1 Writing – review & editing Data curation Resources ShenChuanlai 2 * † ‡ Supervision Project administration Writing – review & editing Writing – original draft Conceptualization Department of Obstetrics and Gynecology, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China Correspondence: Genju Wang, wanggenju@sina.com; Chuanlai Shen, chuanlaishen@seu.edu.cn

These authors have contributed equally to this work

ORCID: Chuanlai Shen, orcid.org/0000-0002-3748-3742

 09 02 2026 2026 17 1792686 21 01 2026 23 01 2026 Copyright © 2026 Wang, Yue, Zhang, Wu, Ji, Zhou, Ji and Shen. 2026 Wang, Yue, Zhang, Wu, Ji, Zhou, Ji and Shen https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Comparison of HBV-specific T cell reactivity across the pregnant, postpartum and non-pregnant women with chronic HBV infection By Wang G, Yue F, Zhang Z, Wu Y, Ji R, Zhou G, Ji Y and Shen C (2024). Front. Immunol. 15:1461767. doi: 10.3389/fimmu.2024.1461767 chronic hepatitis B infection pregnancy antigen-specific T cell detection ELISpot assay postpartum women section-at-acceptance Viral Immunology

There was a mistake in Figure 2 as published, which contains duplicate photographs “pools 1 and 3 for patient 1”. The corrected Figure 2 appears below.

Dot plots of IFN-γ ELISpot assay for six representative pregnant patients with chronic HBV infection. PBMCs from each patient were seed into 10 wells and co-cultured for 20 hours with no peptide, eight peptide pools and PHA, respectively. Then IFN-γ was detected by ELISpot assay. PHA, Phytohemagglutinin.

Rows of circular samples display test results for six patients, labeled by treatment type: Negative No peptide, Pools 1-8, and Positive PHA. Each circle contains red spots, indicating activity level, with numbers quantifying reactivity.

The original version of this article has been updated.

Additional information was omitted and has been added in an Acknowledgments section, which reads as follows:

“The present study builds on our prior work (25), submitted to the Chinese Journal of Microbiology & Immunology on August 30, 2023 and published on September 30, 2024. In the latter study, conducted from September 2022 to June 2023, we tested 100 patients, including 43 pregnant women (pregnant group), 26 patients giving birth within six months (postpartum group), and 31 non-pregnant patients at childbearing age (non-pregnant group) using the in-house ELISpot assay to compare HBV-specific T cell reactivity across the three groups. That study concluded that pregnancy reduced HBV-specific T cell reactivity in the women with chronic HBV infection, but NUC treatment may have improved specific T-cell function.

The present study commenced after July, 2023, enrolling new patients to further confirm our previous findings. Finally, 283 HBV-infected patients (129 pregnant patients, 58 postpartum patients giving birth within six months, and 96 non-pregnant patients) were tested using the in-house ELISpot assay. This study was submitted to Frontiers in Immunology on July 9, 2024, and differs from our prior study in its conclusions: here, we found that while pregnancy can reduce HBV-specific T cell reactivity in women with chronic HBV infection, NUC treatment did not improve their HBV-specific T cell reactivity.

Two independent cohorts (100 patients in the first study, and 283 patients in the present study) were enrolled in these studies.”

The original version of this article has been updated.

[25] Wang G, Wu Y, Ji R, Yue F, Jiang H. Comparison of HBV-specific T cell reactivity among pregnant, postpartum and non-pregnant women at childbearing age with chronic HBV infection. Chin J Microbiol Immunol. (2024) 44:784–91. doi: 10.3760/cma.j.cn112309-20230830-00058.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Edited and reviewed by: Marcelo A. Soares, National Cancer Institute (INCA), Brazil